MD Biosciences Blog

MD Biosciences Adds Myocardial Infarct Models to its Porfolio

Posted by Amy Clausen on Mar 4, 2009 11:03:00 AM


Wednesday, March 4, 2009, St. Paul, MN - MD Biosciences, a Preclinical Contract Research Organization (CRO), announces today that it has expanded its preclinical contract research services by launching a line of in vivo models for the study of myocardial infarct and vascular disease. These models enable the evaluation of drug treatment for myocardial infarct.
New models include:
-       Ligation induced acute cardiac infarction
-       Coil-induced acute cardiac infarction
-       Balloon-induced cardiac ischemia reperfusion
-       Multi-focal myocardial infarct
-       Induction of vascular disease

 

These models offer the flexibility of protocol design for monitoring a variety of parameters such as ECG, invasive blood pressure, SpO2, ETCO2, and PPV. Readouts offered include ECG, Echo, Angiography, cardiac MRI and blood tests for relevant parameters such as CPK. All tests are analyzed by expert cardiologists in collaboration with the Heart Institute, Sheba Medical Center of the Tel Aviv University.

The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays. eba Medical Center of the Tel Aviv University.

The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays.

About MD Biosciences
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.

 

--------

 

 

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Topics: Cardiovascular